Clinical Trial

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC). The aim is to determine whether differences in tracer uptake can be detected between these groups, as translational studies indicate that HER2-mutated tumors may internalize trastuzumab-based agents more efficiently than tumors that solely overexpressed HER2.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2030-06-01 -> 2030-07-07 2026-08-12
minor Completion pushed: 2030-06-01 -> 2030-07-07 2026-08-12
Trial Details
NCT Number NCT07436858
Lead Sponsor The Netherlands Cancer Institute
Conditions Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
Enrollment 20 participants
Start Date 2026-09-07
Primary Completion 2030-07-07 (estimated)
Study Completion 2030-07-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11